Literature DB >> 26537122

Extensively and pan-drug resistant Pseudomonas aeruginosa keratitis: clinical features, risk factors, and outcome.

Merle Fernandes1, Divya Vira2, Radhika Medikonda2, Nagendra Kumar3.   

Abstract

BACKGROUND: Emergence of multi-drug resistant (MDR), extensively drug resistant (XDR), and pan-drug resistant (PDR) strains of Pseudomonas aeruginosa pose a significant therapeutic challenge. Managing XDR and PDR Pseudomonas aeruginosa keratitis would be extremely difficult due to paucity of safe and effective topical medications. We aim to describe the clinical features, risk factors, and outcome of XDR and PDR Pseudomonas aeruginosa keratitis.
METHODS: A retrospective chart review of consecutive cases of XDR and PDR Pseudomonas aeruginosa keratitis were identified from Ocular Microbiology Department. XDR and PDR were defined based on criteria established by Centers for Disease Control and European Centre for Disease Prevention and Control. The following data was collected: age, gender, occupation, symptom duration, systemic and ocular risk factors, infiltrate characteristics, antimicrobial susceptibility, complications, surgical interventions, presenting, and final visual acuity and final outcome. Complete success was defined as resolution of the infiltrate with scar formation on medical treatment alone. Partial success was the resolution following tissue adhesive application. Failure was an inadequate response to medical therapy with progressive increase in infiltrate, corneal melting, and/or perforation necessitating one or more therapeutic penetrating keratoplasties or evisceration.
RESULTS: Fifteen eyes of 13 patients were included. Seven (53.8 %) were male with left eye involvement in nine (60 %) cases. Most common risk factors were bandage contact lens (6, 40 %), topical steroids (5, 33.3 %), previous therapeutic graft (4, 26.6 %), and ocular surface disorder (OSD) following Stevens Johnson Syndrome (SJS) (4, 26.6 %). Of 15 isolates, six (40 %) were sensitive only to imipenem, three (20 %) to colistin, two (13.3 %) to neomycin, one (6.7 %) each to imipenem and colistin, imipenem and ceftazidime, and azithromycin respectively. One isolate was resistant to all antibiotics. Complete success was noted in two (16.67 %), partial success in three (25 %) and failure in seven (58.33 %) eyes. Five (33.3 %) eyes healed on imipenem (three eyes), azithromycin (one eye), and imipenem and colistin (one eye).
CONCLUSION: XDR and PDR Pseudomonas aeruginosa keratitis are extremely difficult to treat. Globe salvage was possible in all cases; however, more than half required therapeutic grafts. Close monitoring of patients with known ocular and systemic factors is warranted.

Entities:  

Keywords:  Extensive drug resistance; Microbial keratitis; Multi-drug resistance; Pan-drug resistance; Pseudomonas aeruginosa

Mesh:

Substances:

Year:  2015        PMID: 26537122     DOI: 10.1007/s00417-015-3208-7

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  30 in total

Review 1.  Contact lens-related microbial keratitis: how have epidemiology and genetics helped us with pathogenesis and prophylaxis.

Authors:  F Stapleton; N Carnt
Journal:  Eye (Lond)       Date:  2011-12-02       Impact factor: 3.775

2.  Multiresistant Pseudomonas keratitis.

Authors:  Jae Yee Ku; Peter Kim; Jonathan Tong; Alfred Wechsler; Peter McCluskey
Journal:  Clin Exp Ophthalmol       Date:  2010-11       Impact factor: 4.207

3.  Microbiological and clinical profiles of patients with microbial keratitis residing in nursing homes.

Authors:  V Jhanji; M Constantinou; H R Taylor; R B Vajpayee
Journal:  Br J Ophthalmol       Date:  2009-07-01       Impact factor: 4.638

Review 4.  Pathogenesis and therapy of Pseudomonas aeruginosa keratitis.

Authors:  J K Dart; D V Seal
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

5.  Ciprofloxacin-resistant Pseudomonas keratitis.

Authors:  P Garg; S Sharma; G N Rao
Journal:  Ophthalmology       Date:  1999-07       Impact factor: 12.079

6.  Kinetics of corneal epithelial regeneration. II. Epidermal growth factor and topical corticosteroids.

Authors:  P C Ho; J H Elliott
Journal:  Invest Ophthalmol       Date:  1975-08

7.  The impact of inoculation parameters on the pathogenesis of contact lens-related infectious keratitis.

Authors:  Connie Tam; James J Mun; David J Evans; Suzanne M J Fleiszig
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-03       Impact factor: 4.799

Review 8.  Superbugs in the coming new decade; multidrug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp. and Pseudomonas aeruginosa in 2010.

Authors:  Patrice Nordmann; Thierry Naas; Nicolas Fortineau; Laurent Poirel
Journal:  Curr Opin Microbiol       Date:  2007-08-30       Impact factor: 7.934

9.  Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases.

Authors:  T Bourcier; F Thomas; V Borderie; C Chaumeil; L Laroche
Journal:  Br J Ophthalmol       Date:  2003-07       Impact factor: 4.638

10.  Emerging moxifloxacin resistance in Pseudomonas aeruginosa keratitis isolates in South India.

Authors:  Catherine E Oldenburg; Prajna Lalitha; Muthiah Srinivasan; Revathi Rajaraman; Meenakshi Ravindran; Jeena Mascarenhas; Durga S Borkar; Kathryn J Ray; Michael E Zegans; Stephen D McLeod; Travis C Porco; Thomas M Lietman; Nisha R Acharya
Journal:  Ophthalmic Epidemiol       Date:  2013-05-10       Impact factor: 1.648

View more
  26 in total

Review 1.  The persistent dilemma of microbial keratitis: Global burden, diagnosis, and antimicrobial resistance.

Authors:  Lawson Ung; Paulo J M Bispo; Swapna S Shanbhag; Michael S Gilmore; James Chodosh
Journal:  Surv Ophthalmol       Date:  2018-12-24       Impact factor: 6.048

2.  Red Eye: A Guide for Non-specialists.

Authors:  Andreas Frings; Gerd Geerling; Marc Schargus
Journal:  Dtsch Arztebl Int       Date:  2017-04-28       Impact factor: 5.594

3.  The ThiL enzyme is a valid antibacterial target essential for both thiamine biosynthesis and salvage pathways in Pseudomonas aeruginosa.

Authors:  Hyung Jun Kim; Hyunjung Lee; Yunmi Lee; Inhee Choi; Yoonae Ko; Sangchul Lee; Soojin Jang
Journal:  J Biol Chem       Date:  2020-05-13       Impact factor: 5.157

4.  Cationic polymer contributes to broaden the spectrum of vancomycin activity achieving eradication of Pseudomonas aeruginosa.

Authors:  Melisa B Corti; Luciana P Campagno; Verónica L Romero; Silvina Gutierrez; Fabiana L Alovero
Journal:  Arch Microbiol       Date:  2022-07-20       Impact factor: 2.667

5.  Topical Review: Contact Lens Eye Health and Safety Considerations in Government Policy Development.

Authors:  Carol Lakkis; Kathrine Osborn Lorenz; Michael Mayers
Journal:  Optom Vis Sci       Date:  2022-09-06       Impact factor: 2.106

6.  Host-microbe interactions in cornea.

Authors:  Linda D Hazlett; Shunbin Xu; Mallika Somayajulu; Sharon A McClellan
Journal:  Ocul Surf       Date:  2021-10-04       Impact factor: 6.268

7.  Challenges of corneal infections.

Authors:  L Hazlett; Susmit Suvas; Sharon McClellan; Sandamali Ekanayaka
Journal:  Expert Rev Ophthalmol       Date:  2016-06-30

8.  Antimicrobial susceptibility and minimal inhibitory concentration of Pseudomonas aeruginosa isolated from septic ocular surface disease in different animal species.

Authors:  L Leigue; F Montiani-Ferreira; B A Moore
Journal:  Open Vet J       Date:  2016-11-15

9.  Antimicrobial Blue Light Therapy for Infectious Keratitis: Ex Vivo and In Vivo Studies.

Authors:  Hong Zhu; Irene E Kochevar; Irmgard Behlau; Jie Zhao; Fenghua Wang; Yucheng Wang; Xiaodong Sun; Michael R Hamblin; Tianhong Dai
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-01-01       Impact factor: 4.799

10.  Attenuation of Pseudomonas aeruginosa biofilm formation by Vitexin: A combinatorial study with azithromycin and gentamicin.

Authors:  Manash C Das; Padmani Sandhu; Priya Gupta; Prasenjit Rudrapaul; Utpal C De; Prosun Tribedi; Yusuf Akhter; Surajit Bhattacharjee
Journal:  Sci Rep       Date:  2016-03-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.